The latest price target for AbbVie (NYSE:ABBV) was reported by Piper Sandler on December 17, 2024. The analyst firm set a price target for $220.00 expecting ABBV to rise to within 12 months (a possible 25.71% upside). 50 analyst firms have reported ratings in the last year.

The latest analyst rating for AbbVie (NYSE:ABBV) was provided by Piper Sandler, and AbbVie maintained their overweight rating.

The last upgrade for AbbVie Inc happened on November 22, 2024 when Leerink Partners raised their price target to $206. Leerink Partners previously had a market perform for AbbVie Inc.

The last downgrade for AbbVie Inc happened on December 18, 2023 when HSBC changed their price target from $167 to $156 for AbbVie Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.

While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a maintained with a price target of $212.00 to $220.00. The current price AbbVie (ABBV) is trading at is $175.00, which is out of the analyst’s predicted range.